SG152274A1 - Dalbavancin compositions for treatment of bacterial infections - Google Patents

Dalbavancin compositions for treatment of bacterial infections

Info

Publication number
SG152274A1
SG152274A1 SG200902872-1A SG2009028721A SG152274A1 SG 152274 A1 SG152274 A1 SG 152274A1 SG 2009028721 A SG2009028721 A SG 2009028721A SG 152274 A1 SG152274 A1 SG 152274A1
Authority
SG
Singapore
Prior art keywords
treatment
bacterial infections
dalbavancin compositions
dalbavancin
compositions
Prior art date
Application number
SG200902872-1A
Other languages
English (en)
Inventor
Martin Stogniew
Luigi Colombo
Romeo Ciabatti
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of SG152274A1 publication Critical patent/SG152274A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG200902872-1A 2004-04-27 2005-04-26 Dalbavancin compositions for treatment of bacterial infections SG152274A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/834,395 US7119061B2 (en) 2002-11-18 2004-04-27 Dalbavancin compositions for treatment of bacterial infections

Publications (1)

Publication Number Publication Date
SG152274A1 true SG152274A1 (en) 2009-05-29

Family

ID=36692659

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200902872-1A SG152274A1 (en) 2004-04-27 2005-04-26 Dalbavancin compositions for treatment of bacterial infections

Country Status (17)

Country Link
US (2) US7119061B2 (ru)
EP (1) EP1748786A4 (ru)
JP (2) JP5207734B2 (ru)
KR (2) KR100930982B1 (ru)
CN (1) CN1964736B (ru)
AU (2) AU2005325261B2 (ru)
BR (1) BRPI0510269B8 (ru)
CA (1) CA2564112C (ru)
HK (1) HK1103639A1 (ru)
IL (1) IL178207A (ru)
MX (1) MXPA06012301A (ru)
NO (1) NO345529B1 (ru)
NZ (2) NZ550053A (ru)
RU (2) RU2352353C2 (ru)
SG (1) SG152274A1 (ru)
WO (1) WO2006078277A2 (ru)
ZA (2) ZA200607888B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090433A1 (en) 2002-11-18 2005-04-28 Vicuron Pharmaceuticals, Inc Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103087918B (zh) * 2013-02-20 2015-04-22 广州市微生物研究所 一种好氧反硝化菌剂及其制备与应用
EP2969004A4 (en) 2013-03-15 2016-09-21 Melinta Therapeutics Inc METHOD FOR THE TREATMENT OF INFECTIONS IN OVERWEIGHT AND ADIPOSIVE PATIENTS USING ANTIBIOTICS
EP3107533A4 (en) 2014-02-18 2017-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
WO2016011245A1 (en) * 2014-07-17 2016-01-21 The Medicines Company High purity oritavancin and method of producing same
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
WO2017194385A1 (en) 2016-05-09 2017-11-16 Xellia Pharmaceuticals Aps Stabilized glycopeptide antibiotic formulations
RU2019119405A (ru) * 2016-11-23 2020-12-25 Гуфик Байосайенсиз Лимитед Лиофилизированные фармацевтические композиции далбаванцина
CN109946398B (zh) * 2019-03-28 2022-05-24 丽珠集团新北江制药股份有限公司 一种检测达巴万星及其杂质的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN111686240B (zh) * 2020-06-14 2021-04-09 中国科学院昆明动物研究所 达巴万星在制备抑制SARS-CoV-2与ACE2结合的药物中的应用
CN115219626A (zh) * 2022-07-18 2022-10-21 丽珠集团福州福兴医药有限公司 达巴万星合成反应的分析方法
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1496386A (en) 1975-03-05 1977-12-30 Lepetit Spa Antibiotics
US4195079A (en) 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
FI73697C (fi) 1982-06-08 1987-11-09 Lepetit Spa Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2.
FR2548021B1 (fr) 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8415092D0 (en) 1984-06-13 1984-07-18 Lepetit Spa Ester derivatives
GB8425685D0 (en) 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
GB8428619D0 (en) 1984-11-13 1984-12-19 Lepetit Spa Derivatives of antibiotic l 17046
US4914187A (en) 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
GB8512795D0 (en) 1985-05-21 1985-06-26 Lepetit Spa Increasing ratio of components of teicoplanin a2 complex
GB8531846D0 (en) 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608809D0 (en) 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
GB8621911D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GB8621912D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
GB8715735D0 (en) 1987-07-03 1987-08-12 Lepetit Spa De-mannosyl teicoplanin derivatives
US4882313A (en) 1987-07-31 1989-11-21 Smithkline Beckman Corporation Carboxamide derivatives of glycopeptides
GB8726859D0 (en) 1987-11-17 1987-12-23 Lepetit Spa 22-dechlorotei-coplanins
DE68925806T2 (de) 1988-12-27 1996-09-26 Lepetit Spa C63-Amidderivate von 34-de(acetylglucosaminyl)-34-deoxy-teicoplaninen
IE64155B1 (en) 1989-03-29 1995-07-12 Lepetit Spa New substituted alkylamide derivatives of teicoplanin
JPH03193735A (ja) * 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
US5030619A (en) 1990-04-16 1991-07-09 Miles Inc. Synergistic fungicidal composition
US5606036A (en) 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
DK0596929T3 (da) * 1991-07-29 1995-09-11 Lepetit Spa Amidderivater af antibiotikum A 40926
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US6384013B1 (en) 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5882900A (en) 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CN1036654C (zh) * 1993-01-01 1997-12-10 格鲁波莱佩蒂特公司 抗菌素a40926的酰氨衍生物及其制备方法
JP3518606B2 (ja) 1995-02-07 2004-04-12 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ Ｇｅ２２７０及びｇｅ２２７０−様抗生物質の塩基性オキサゾリン−アミド誘導体
EP0801655B1 (en) 1995-02-07 1998-04-15 Biosearch Italia S.p.A. Basic proline-amide derivatives of ge 2270 and ge 2270-like antibiotics
KR19990082541A (ko) 1996-02-14 1999-11-25 클라우디오 쿼르타 항생물질 ge2270 c2a, d2 및 e 인자의 유도체
AU2441697A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Covalently-linked glycopeptide dimers
CA2250578C (en) 1996-04-23 2003-06-24 Versicor Inc. Improved chemical process for preparing amide derivatives of antibiotic a 40926
US5935238A (en) 1997-06-19 1999-08-10 Sun Microsystems, Inc. Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles
CA2255140A1 (en) 1997-12-23 1999-06-23 Eli Lilly And Company Echinocandin binding domain of 1,3-.beta.-glucan synthase
US6417180B1 (en) * 1998-10-07 2002-07-09 University Of Massachusetts Zinc finger-reactive antimicrobial compounds
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
DE60139339D1 (de) * 2000-11-07 2009-09-03 Novartis Vaccines & Diagnostic Stabilisierte interferonzusammensetzungen
US20050090433A1 (en) 2002-11-18 2005-04-28 Vicuron Pharmaceuticals, Inc Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections

Also Published As

Publication number Publication date
NZ550053A (en) 2011-01-28
US7119061B2 (en) 2006-10-10
RU2006136736A (ru) 2008-06-10
JP2013014613A (ja) 2013-01-24
NO20064287L (no) 2006-10-24
CN1964736A (zh) 2007-05-16
JP5207734B2 (ja) 2013-06-12
HK1103639A1 (en) 2007-12-28
IL178207A0 (en) 2007-07-04
MXPA06012301A (es) 2007-03-15
EP1748786A4 (en) 2009-07-15
ZA200607888B (en) 2008-03-26
CA2564112C (en) 2014-08-05
JP2007534768A (ja) 2007-11-29
IL178207A (en) 2014-05-28
AU2005325261B2 (en) 2010-11-11
BRPI0510269B1 (pt) 2019-08-06
CA2564112A1 (en) 2006-07-27
KR100930982B1 (ko) 2009-12-10
ZA200607889B (en) 2007-12-27
EP1748786A2 (en) 2007-02-07
AU2011200423B2 (en) 2012-11-29
BRPI0510269A (pt) 2007-10-30
NO345529B1 (no) 2021-03-29
WO2006078277A2 (en) 2006-07-27
BRPI0510269B8 (pt) 2021-05-25
RU2352353C2 (ru) 2009-04-20
AU2005325261A1 (en) 2006-07-27
KR20070015179A (ko) 2007-02-01
RU2008142899A (ru) 2010-05-10
WO2006078277A3 (en) 2006-10-19
CN1964736B (zh) 2012-07-04
AU2011200423A1 (en) 2011-02-24
US20050004051A1 (en) 2005-01-06
US20050004050A1 (en) 2005-01-06
NZ588109A (en) 2012-05-25
KR20080048093A (ko) 2008-05-30

Similar Documents

Publication Publication Date Title
SG152274A1 (en) Dalbavancin compositions for treatment of bacterial infections
AU2003298662A1 (en) Dalbavancin compositions for treatment of bacterial infections
TW200734344A (en) Antibacterial agents
TW200630367A (en) Substituted adenines and the uses thereof
PL1765391T3 (pl) Kompozycje bakteryjne do leczenia nowotworów
WO2007017267A3 (en) Novel compounds
GB2430935A (en) Tetrapeptide analogs
SG156689A1 (en) Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
EP3812372A3 (en) 7-heterocyclyl substituted sancycline derivatives for treating bacterial, viral and parasitic infections (e.g. malaria) or inflammatory diseases
SG149855A1 (en) N-channel transistor
MXPA05008126A (es) Inhibidores de girasa y uso de los mismos.
HK1115590A1 (en) Triazolophthalazines
WO2006120563A3 (en) Antibacterial agents
UA88638C2 (ru) Бета-карболины, полезные для лечения воспалительного заболевания
ZA200704392B (en) Antibiotic combinations for providing total solution to the treatment of infections
GB0513096D0 (en) Treatment of microbial infections
ZA200704775B (en) Compositions for treatment of ear infections
SG142306A1 (en) Methods for neuroprotection
IL180459A0 (en) Treatment of bacterial infections
GB2401788B (en) Treatment of surfaces populated by bacteria
MX2009009074A (es) Macrolidos basados en eritromicina.
AU2003250522A1 (en) Compositions and methods for treatment and prophylaxis of infections caused by gram positive bacteria
WO2008142102A3 (en) Use of transferrin for preparing pharmaceutical compositions useful for treating bacterial infections as coadjuvants in antibiotic therapy